Loading…

Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis

Abstract Management of cardiac sarcoidosis (CS) can be challenging. The first-line therapy for this condition is corticosteroids, but other immunosuppressive agents are sometimes co-administered to reduce the dosage of corticosteroid and to thereby avoid steroid-induced adverse effects or to increas...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiology cases 2016-04, Vol.13 (4), p.125-128
Main Authors: Kikuchi, Noriko, MD, Nunoda, Shinichi, MD, PhD, FJCC, Serizawa, Naoki, MD, PhD, Suzuki, Atsushi, MD, PhD, Suzuki, Tsuyoshi, MD, PhD, Fukushima, Kenji, MD, PhD, Uto, Kenta, MD, PhD, Shiga, Tsuyoshi, MD, PhD, FJCC, Shoda, Morio, MD, PhD, Hagiwara, Nobuhisa, MD, PhD, FJCC
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Management of cardiac sarcoidosis (CS) can be challenging. The first-line therapy for this condition is corticosteroids, but other immunosuppressive agents are sometimes co-administered to reduce the dosage of corticosteroid and to thereby avoid steroid-induced adverse effects or to increase its therapeutic efficacy. Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase that acts more selectively on T and B lymphocytes when compared with azathioprine. A 40-year-old man was diagnosed with CS after presenting with ventricular fibrillation. His left ventricular ejection fraction was severely reduced (30%), and cardiac positron emission tomography (PET) showed abnormal uptake of18 F-fluorodeoxyglucose. A cardioverter-defibrillator was implanted and prednisolone (30 mg/day) was administered. He was re-admitted with recurrent sustained ventricular tachycardia and a positive PET finding despite a 5-month course of prednisolone, and MMF (1000 mg/day) was administered. Six months later, he had not required re-hospitalization for heart failure or arrhythmia. We conclude that combination therapy with MMF and corticosteroids is useful for refractory CS. < Learning objective: Management of cardiac sarcoidosis (CS) can be challenging. Although some immunosuppressive agents are co-administered to reduce the dosage of corticosteroids or to intensify the effect of corticosteroids, the optimal combination regimen has not yet been established. This case report shows that combination therapy with corticosteroid and mycophenolate mofetil was useful for CS that was refractory to corticosteroid monotherapy.>
ISSN:1878-5409
1878-5409
DOI:10.1016/j.jccase.2015.12.008